Manufacturers announce study results suggesting long-acting cabotegravir superior to standard of care for pre-exposure prophylaxis (PrEP) in women

In the HPTN 084 trial, the independent data safety monitoring board recommended early unblinding as cabotegravir met the primary objective of demonstrating superiority to daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (89% more effective) for PrEP.

Source:

PharmaTimes